Disease‐specific adverse events · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pneumonia and other serious adverse events · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
24 participants
GRADE not reported
Adverse events: number of people with 1 or more (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes adverse events: number of people with 1 or more (all‐cause) compared with usual care (very low certainty).
1 finding from 1 review
Adverse events · autumn asthma exacerbations in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · autumn asthma exacerbations in children
Omalizumab showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Adverse events · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Adverse events · autumn asthma exacerbations in children
Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).
1 finding from 1 review
All adverse events · acute asthma exacerbation
Antibiotics showed no clear difference in all adverse events compared with placebo or usual care (low certainty).
1 finding from 1 review
Adverse events (all) · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: mortality · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
1 finding from 1 review
Number experiencing adverse effects · the management of chronic obstructive pulmonary disease
It is very uncertain whether multi‐component intervention changes adverse events: number of people experiencing an AE compared with other intervention or routine, usual care or control treatment (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · the management of chronic obstructive pulmonary disease
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing a serious adverse event compared with other intervention or routine, usual care or control treatment (low certainty).
1 finding from 1 review
Minor adverse events assessed: related to intervention only (e.g. redness) · COPD
NMES showed no clear difference in minor adverse events assessed: related to intervention only (e.g.… compared with usual care (with or without sham NMES) (low certainty).
1 finding from 1 review